{
    "clinical_study": {
        "@rank": "5121", 
        "brief_summary": {
            "textblock": "RATIONALE: Vaccines made from a person's white blood cells may make the body build an immune\n      response to kill cancer cells.\n\n      PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients\n      who have chronic myelogenous leukemia."
        }, 
        "brief_title": "Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia", 
        "condition": "Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the feasibility of vaccination with autologous heat shock protein 70 in\n           patients with chronic phase chronic myelogenous leukemia.\n\n        -  Determine the toxicity of this vaccination in these patients.\n\n      OUTLINE: Patients undergo leukapheresis to obtain peripheral mononuclear cells (PMNCs). Heat\n      shock protein 70 (HSP70) is derived from the autologous PMNCs. Patients receive HSP70\n      intradermally once weekly for 8 weeks.\n\n      Patients are followed for 2 weeks.\n\n      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Diagnosis of chronic phase chronic myelogenous leukemia\n\n               -  Philadelphia chromosome positive\n\n          -  Peripheral blast count no greater than 10%\n\n          -  No molecular remission\n\n          -  Less than 3 years since initial diagnosis\n\n          -  No anticipation of requirement for bone marrow or stem cell transplantation for 6\n             months\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-1\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Hemoglobin at least 10 g/dL\n\n          -  Platelet count at least 20,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin less than 2.0 times upper limit of normal (ULN)\n\n          -  Transaminase less than 2.0 times ULN\n\n        Renal:\n\n          -  Creatinine less than 2.0 mg/dL\n\n        Other:\n\n          -  Not pregnant\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  No significant active infection requiring hospitalization\n\n          -  No other serious illness or significant behavioral or psychological problem that\n             would preclude study involvement\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  See Disease Characteristics\n\n          -  Prior interferon alfa allowed\n\n          -  No concurrent interferon alfa\n\n        Chemotherapy:\n\n          -  Prior cytarabine or other cytotoxic agents allowed\n\n          -  No concurrent cytarabine or other cytotoxic agents\n\n          -  Concurrent hydroxyurea allowed\n\n        Endocrine therapy:\n\n          -  No concurrent corticosteroid therapy\n\n        Radiotherapy:\n\n          -  Not specified\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  No concurrent immunosuppressive medications\n\n          -  Concurrent imatinib mesylate allowed"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "February 14, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00030303", 
            "org_study_id": "CDR0000069127", 
            "secondary_id": [
                "UCHC-01117", 
                "UCHC-7659", 
                "NCI-V01-1685"
            ]
        }, 
        "intervention": {
            "intervention_name": "recombinant 70-kD heat-shock protein", 
            "intervention_type": "Biological"
        }, 
        "keyword": [
            "chronic phase chronic myelogenous leukemia", 
            "chronic myelogenous leukemia, BCR-ABL1 positive"
        ], 
        "lastchanged_date": "June 4, 2011", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/UCHC-01117"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Farmington", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06030-1601"
                }, 
                "name": "University of Connecticut Health Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Feasibility And Toxicity Study Of Vaccination With HSP70 For The Treatment Of Chronic Myelogenous Leukemia In Chronic Phase", 
        "overall_official": {
            "affiliation": "University of Connecticut Health Center", 
            "last_name": "Zihai Li, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00030303"
        }, 
        "results_reference": {
            "citation": "Li Z, Qiao Y, Laska E, et al.: Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein 70 vaccine for chronic myelogenous leukemia. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-664, 2003."
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Connecticut Health Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2001", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2003"
    }, 
    "geocoordinates": {
        "University of Connecticut Health Center": "41.728 -72.84"
    }
}